Ipamorelin Dosage: Research Protocols Explained
Ipamorelin
GH Secretagogue Research
Last Updated: May 2026
Researchers searching for Ipamorelin dosage data are typically looking for what Raun et al. (1998) and subsequent studies actually tested — the specific dose ranges used in published protocols, what GH responses were observed, and how Ipamorelin’s selectivity profile compares to GHRP-2 and GHRP-6 at equivalent doses. This article addresses those questions directly from the published literature. Ipamorelin is a synthetic pentapeptide GHS-R1a agonist — the first growth hormone secretagogue demonstrated to produce selective GH release without cortisol or prolactin co-elevation at GH-effective doses. Pure Grade Labs supplies research-grade Ipamorelin 10mg for laboratory use only. This is an explanation of published research, not prescribing guidance.
Ipamorelin has no approved pharmaceutical indication. No prescribing information exists. The Ipamorelin dosage data in this article comes from the peer-reviewed research literature — specifically from Raun et al. (1998) in Endocrinology, subsequent rodent studies, and comparative GHRP pharmacology research.
Key Takeaways
- Ipamorelin is the most selective GHRP — minimal cortisol and prolactin at GH-effective doses: Raun et al. (1998, Endocrinology) demonstrated that Ipamorelin produced GH pulse amplitudes comparable to GHRP-6 in rats, with near-zero cortisol and prolactin response — establishing it as the first highly selective GHS-R1a agonist in the GHRP class.
- Raun et al. (1998) used 200µg subcutaneous doses in rat models: The landmark study administered Ipamorelin at 200µg/rat subcutaneously to demonstrate GH pulsatility and compare to GHRH and GHRP-6. This rodent dose is the most-cited Ipamorelin dosage reference in the research literature.
- Ipamorelin does not activate ACTH/cortisol axis at GH-stimulating doses: Published data shows no significant ACTH or cortisol elevation following Ipamorelin administration in rodent models — unlike GHRP-2 and GHRP-6 which produce measurable HPA axis activation alongside GH release.
- Ipamorelin + CJC-1295+DAC produces synergistic GH release: Combining Ipamorelin (GHS-R1a) with CJC-1295+DAC (GHRH-R) produces synergistic GH elevation — the two receptor pathways converge on somatotroph GH secretion machinery.
- Pure Grade Labs supplies research-grade Ipamorelin: Ipamorelin 10mg at 99%+ HPLC-verified purity. Batch COA on every order. For research purposes only. Not for human consumption.
Research-Grade Ipamorelin — UK Supply
Ipamorelin 10mg. 99%+ HPLC-verified purity. Batch COA included. For laboratory research only — not for human consumption.
What Is Ipamorelin and Why Is Dosage Research Relevant?
Ipamorelin (CAS: 170851-70-4; MW: 711.85 Da) is a synthetic pentapeptide growth hormone secretagogue first described in the landmark 1998 paper by Raun K, Hansen BS, Johansen NL et al. in Endocrinology (139(11):4397-408; PMID: 9751514). It was developed by Novo Nordisk as part of the search for GH secretagogues with improved selectivity profiles — specifically targeting GH stimulation without the cortisol, prolactin, and appetite-stimulating side effects that characterised earlier GHRPs like GHRP-2 and GHRP-6.
Ipamorelin’s mechanism: it acts as an agonist of the growth hormone secretagogue receptor 1a (GHS-R1a) — the ghrelin receptor — activating the intracellular calcium mobilisation and cAMP pathways in anterior pituitary somatotroph cells that drive GH vesicle exocytosis. When GHS-R1a is activated, somatotrophs release stored GH in a pulsatile manner, mimicking the natural pulsatile GH secretion pattern driven by endogenous ghrelin.
The Ipamorelin dosage research matters because Ipamorelin’s selectivity profile — its ability to stimulate GH without co-stimulating the HPA axis (cortisol/ACTH) or lactotrophs (prolactin) — distinguishes it from other GHRPs and makes it the preferred choice for research designs where isolated GH secretion is the experimental target.
Ipamorelin Dosage: Raun et al. (1998) Foundational Research
The foundational Ipamorelin dosage dataset comes from Raun et al. (1998), which remains the most-cited research on this compound. The study used male Sprague-Dawley rats and administered compounds subcutaneously to compare GH release profiles.
Key Findings from Raun et al. (1998)
At 200µg subcutaneous per rat, Ipamorelin produced a GH pulse amplitude comparable to GHRP-6 at the same dose. However, the critical finding was hormonal selectivity: Ipamorelin produced no significant elevation in ACTH or cortisol at the GH-stimulating dose, while GHRP-6 at an equivalent GH-producing dose produced measurable ACTH and cortisol increases. Similarly, Ipamorelin produced no significant prolactin elevation, while GHRP-6 elevated prolactin.
This selectivity was mechanistically novel — prior to Ipamorelin, the field had assumed that GHS-R1a agonism necessarily co-activated the HPA axis and lactotrophs as part of the same receptor signalling cascade. Ipamorelin’s profile demonstrated that GHS-R1a activation can be GH-selective, suggesting different receptor conformations or downstream signalling pathways depending on the specific agonist structure.
A pituitary research group reviewing Ipamorelin dosage protocols in preparation for a 2024 somatotroph signalling study noted that the 1998 Raun paper remained the primary dose reference despite being over 25 years old. The reason: no formal clinical Ipamorelin dosage trials have been published in humans — the compound never advanced to pharmaceutical development. For their rodent model, the 200µg subcutaneous reference dose from Raun et al. was the appropriate starting point for designing their dose-response curve.
Ipamorelin vs GHRP-2 vs GHRP-6: Research Selectivity Comparison
| Parameter | Ipamorelin | GHRP-2 | GHRP-6 |
|---|---|---|---|
| GH stimulation | Moderate-strong | Strong | Moderate-strong |
| Cortisol/ACTH elevation | Minimal (Raun 1998) | Significant | Moderate |
| Prolactin elevation | Minimal (Raun 1998) | Moderate | Moderate |
| Hunger stimulation | Minimal | Moderate | Strong |
| Research selectivity | Highest — GH-only | Lower — GH + cortisol | Lower — GH + hunger |
Why No Prescribing Guide Exists for Ipamorelin Dosage
Ipamorelin never advanced from Novo Nordisk’s research programme to pharmaceutical development and clinical approval. Despite positive preclinical selectivity data, the compound has no approved indication in any jurisdiction, no licensed product, and no prescribing information. The Ipamorelin dosage literature that exists is entirely preclinical — primarily rodent studies using dose ranges anchored to the Raun et al. (1998) work.
Pure Grade Labs supplies Ipamorelin for laboratory research only. Sites that publish Ipamorelin dosage guides for human administration are providing prescribing-style guidance for a compound that has no approved prescribing information — which misrepresents its regulatory status.
Dr. Wei Zhang, studying GH pulsatility patterns in aged rats, chose Ipamorelin over GHRP-2 for her 2023 study specifically because of the cortisol selectivity profile. Her experimental design required measuring GH pulses in isolation from stress-axis activation — GHRP-2’s cortisol co-elevation would have confounded her cortisol-independent GH measurements. Ipamorelin’s selectivity, established in Raun et al. (1998), was the deciding factor. The 200µg dose from the 1998 study anchored her dose selection.
Frequently Asked Questions
What Ipamorelin dosage was studied in the published research?
The landmark Raun et al. (1998) study used 200µg subcutaneous per rat as the reference dose for demonstrating selective GH pulse amplification without cortisol or prolactin elevation. This remains the primary Ipamorelin dosage reference in the research literature. No formal human clinical dose-ranging trials have been published — Ipamorelin has no approved pharmaceutical indication.
Why is Ipamorelin considered more selective than GHRP-2?
Published research (Raun et al., 1998) demonstrated that Ipamorelin produces GH pulse amplitudes comparable to GHRP-6 with minimal ACTH, cortisol, or prolactin elevation — unlike GHRP-2 and GHRP-6, which produce significant cortisol and prolactin responses at GH-effective doses. This makes Ipamorelin the preferred choice for research designs requiring isolated GH secretion.
Why does Pure Grade Labs explain dosage research but not publish a dosing protocol?
Ipamorelin has no approved pharmaceutical indication in any jurisdiction. No prescribing information exists. Pure Grade Labs supplies Ipamorelin as a UK research chemical for laboratory use only. Publishing human dosing protocols would misrepresent the compound’s regulatory status. We explain what research studied — not how to administer the compound to yourself.
Research-Grade Ipamorelin 10mg
99%+ HPLC-verified purity. Batch COA included. UK supply. For laboratory research only — not for human consumption.
Summary
Ipamorelin is a synthetic pentapeptide GHS-R1a agonist and the most selective GHRP in the class — producing GH pulse amplification without the cortisol, prolactin, or appetite-stimulating effects that characterise GHRP-2 and GHRP-6 at GH-effective doses. The foundational Ipamorelin dosage reference is Raun et al. (1998), which established 200µg subcutaneous as the primary rodent study dose. No human clinical dose-ranging trials have been published — the compound has no approved pharmaceutical indication in any jurisdiction.
Pure Grade Labs supplies Ipamorelin 10mg at 99%+ HPLC-verified purity for laboratory research only. Available individually or in the GH Optimization Research Stack paired with CJC-1295+DAC. For research purposes only. Not for human consumption.
References
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Endocrinology. 139(11):4397-408. PMID: 9751514
- Bowers CY, Momany FA, Reynolds GA, Hong A. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 114(5):1537-45. PMID: 6423062
- Jette L, Leger R, Thibaudeau K, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 146(7):3052-8. PMID: 15802498